GSK agreed to acquire Rapt Therapeutics for $2.2 billion to secure ozureprubart, a long‑acting anti‑IgE monoclonal antibody in Phase IIb development for food allergies. The deal gives GSK rights outside Greater China and fits the company’s strategy to add potential best‑in‑class assets in allergy and immunology. Rapt’s candidate is designed for extended dosing intervals—every 8–12 weeks versus current two‑to‑four‑week regimens—which could broaden eligibility versus existing anti‑IgE therapies.